Telix Pharmaceuticals (TLX) Stock Forecast: StockMap's 2-Week Call
TLX stock forecast: StockMap's model makes no two-week call on Telix Pharmaceuticals after the Nov 19 close: its evidence is split, 5 reasons for and 10 against. Right in 1 of 4 two-week windows on TLX since Aug 21; by chance, a call on the same dates was right 67% of the time.
Telix Pharmaceuticals last closed at $8.71, -2.79% on the session.
Against the IVW growth benchmark the position is -0.46% over the forecast window.
Telix Pharmaceuticals' market cap is $2.96B as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -6 (too close to call).
Where TLX sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 5 bullish and 10 bearish.
Agreement across those insights is 67%.
19 daily calls for TLX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
Telix Pharmaceuticals is classified under Health Care / Biotechnology.
StockMap tracks Telix Pharmaceuticals as the 70th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Telix Pharmaceuticals ranks 95th of 394 in the group, against a group median of -0.27.